The Swedish firm plans to expand the VIDAR-1 umbrella trial to study additional KRAS-targeting product candidates in the future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback